Skip to main content

CORRECTION article

Front. Oncol., 31 May 2023
Sec. Gynecological Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1228879

Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

This article is a correction to:

  1. Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

    1. Read original article
Jiahua Liu&#x;Jiahua Liu†Junnan Ma&#x;Junnan Ma†Jiarong ZhangJiarong ZhangChengming LiChengming LiBowen YuBowen YuHyok Chol ChoeHyok Chol ChoeKaiyue DingKaiyue DingLiu ZhangLiu ZhangLin Zhang*Lin Zhang*
  • Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China

A corrigendum on
Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

by Liu J, Ma J, Zhang J, Li C, Yu B, Choe HC, Ding K, Zhang L and Zhang L (2023) Front. Oncol. 13:1173863. doi: 10.3389/fonc.2023.1173863

In the published article, there was an error in the Funding statement. In the Funding statement, we left out a funding. The original Funding statement is “This work was supported by grants from the National Natural Science Foundation of China (No. 81873195), the Liaoning Revitalization Talents Program (XLYC1907113), the Natural Science Foundation of Liaoning Province (2023010109-JH2/1013), and the Distinguished Young Scholars in Dalian (2022RJ19).”. The correct Funding statement appears below.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.81873195), the Liaoning Revitalization Talents Program (XLYC1907113), the Natural Science Foundation of Liaoning Province (2023010109-JH2/1013), the Distinguished Young Scholars in Dalian (2022RJ19), and the Dalian Medical University Foundation for Teaching Reform Project of Undergraduate Innovative Talents Training (111906010210).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: drug resistance, ovarian cancer, bibliometric, Citespace, Vosviewer, PARP inhibitors, bevacizumab

Citation: Liu J, Ma J, Zhang J, Li C, Yu B, Choe HC, Ding K, Zhang L and Zhang L (2023) Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022. Front. Oncol. 13:1228879. doi: 10.3389/fonc.2023.1228879

Received: 25 May 2023; Accepted: 26 May 2023;
Published: 31 May 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Liu, Ma, Zhang, Li, Yu, Choe, Ding, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lin Zhang, zhl8247@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.